Consensus statement on the use of clozapine during the COVID-19 pandemic
JournalJournal of psychiatry & neuroscience : JPN
PublisherCanadian Medical Association
MetadataShow full item record
With the ongoing coronavirus disease 2019 (COVID-19) pandemic, psychiatrists find themselves in the clinical situation of being asked by patients, family members and patient advocacy societies to help ensure access to clozapine as a medication critical for ongoing patient care. To provide clozapine prescribing guidance and facilitate regulatory agencies modifying laboratory monitoring and/or dispensing requirements, an expert advisory subgroup of the Treatment Response and Resistance in Psychosis working group developed the following background, recommendations and rationale as a consensus statement.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85083188654&doi=10.1503%2fjpn.200061&partnerID=40&md5=0dc3ecc0fb112ea187d0e82342f634e5; http://hdl.handle.net/10713/12640